Request Consultation
Primarily, big data analytics refers to the collection & analysis of large-volume datasets in pharma companies, which majorly cover biomedical literature, genomic databases, clinical trial results, & electronic health records (EHRs). On the other hand, AI in drug discovery is widely leveraging machine learning & deep learning to study vast biological & chemical datasets. This further speeds up the typical 10-to-15-year drug development cycle, reducing multibillion-dollar expenditures & estimating interactions of molecules with the human body.
Global Big Data Analytics in Healthcare Market Growth
The global big data analytics in healthcare market size is calculated at USD 40.61 billion in 2024, grew to USD 47.42 billion in 2025, and is projected to reach around USD 190.98 billion by 2034. The market is expanding at a CAGR of 16.73% between 2025 and 2034.
According to Towards Healthcare’s Big Data Analytics in Healthcare Market Size, Trends and Competitive Analysis, surging huge volumes of healthcare data from EHRs, medical imaging, wearable devices, & genomic data, along with ongoing government investments in data analytics, are driving the global market expansion.
Global AI in Drug Discovery Market
The global AI in drug discovery market size was evaluated at USD 19.89 billion in 2025 and is expected to attain around USD 160.49 billion by 2035, growing at a CAGR of 23.22% from 2026 to 2035.
According to Towards Healthcare’s AI in Drug Discovery Market Size, Segments Insight and Trends Analysis 2026, the booming burden of chronic disease cases, rising alliances among diverse pharmaceutical industries, and revolutionary reduction in R&D periods by using AI propel the worldwide adoption and advancements in AI-driven drug discovery.
Highlighting Trends in Big Data Analytics & AI in the Drug Discovery Industry
Big Data Analytics
A lucrative trend has been exploring robust analytics that meet patient demographics, medical histories, & genetic profiles with trial requirements, which supports finding study locations with the greatest patient availability
Another trend is covering remote patient monitoring (RPM) & data from wearable devices, which enables pharma leaders for the collection of consistent, real-time health data by reducing dropout counts & optimizing trial effectiveness.
AI in Drug Discovery
Many research activities are stepping towards the use of intelligent agentic systems that autonomously reclaim literature, develop compounds, assess properties, & improve strategies across iterative loops.
Moreover, pharma leaders are extensively unifying AI software with robotic lab hardware to automate the hit-finding & lead-optimization phases. However, pivotal AI algorithms are establishing experimental hypotheses, & robotic systems are implementing them in a continuous, 24/7 loop, iterating tests & learning from the results.
Upcoming Technological Opportunities of Big Data Analytics in the Healthcare Sector
In the coming era, big data analytics will assist in the analysis of a patient's DNA, with vast repositories of clinical data to determine disease possibilities & develop customized treatment strategies. To diagnose malignant spots, cardiovascular issues, or early signs of neurodegenerative diseases from biomedical images by employing deep learning before symptoms even occur also presents a major opportunity in big data analytics.
The globe will focus highly on using Internet of Medical Things (IoMT) & wearables to record real-time physiological data, such as oxygen saturation, blood pressure, ECG, & simplify it directly to cloud analytics systems.
Prominent Research Offerings in AI in Drug Discovery Across the Various Industries
| Company | Description |
| Novartis | It is proceeding with an alliance with Isomorphic Labs to design new drug candidates & use large-scale data to automate clinical development by shortening each trial cycle by at least six months. |
| AstraZeneca | This firm is implementing AI Technologies, including MapDiff and Edge Set Attention for advanced protein design, and also optimising clinical trial design by employing AI agents |
| Pfizer | A leader is increasingly unveiling AI to anticipate epidemiological patterns & simplify global production processes. |
| Bristol Myers | This player is emphasising the integration of large language models company-wide to speed up literature reviews, target identification, & molecule design |
| Schrödinger, Inc. | Its offerings cover a predictive software platform that models protein-ligand binding & spurs lead optimization. |
| Insilico Medicine | This firm highly leverages generative AI & deep learning to find novel drug targets & quickly deliver preclinical candidates in under 18 months. |
| XtalPi | A company offers integration of AI-enabled molecular simulation with automated laboratory robotics. |
Advanced Project on AI in Drug Discovery
- In May 2026, GC Biopharma was selected as a core research partner for a Ministry of Science & ICT-powered project titled ‘Development and Validation of a Multi-Agent AI Platform for the Full Cycle of AI-Driven Drug Discovery.
- In May 2026, the UK Government’s Sovereign AI Fund invested in Isomorphic Labs, a London-based company that utilizes advanced AI in revolutionizing novel drug discovery.
- In January 2026, Abcam & the other 17 members of the partnership introduced the Innovative Health Initiative (IHI) project, LIGAND-AI, to bolster AI-powered drug discovery through open science
Latest Transformative Launches in the Big Data Analytics and AI in Pharmaceutical Drug Discovery Market
- In May 2026, MEDDDICAL rolled out an advisory service that unites pharmaceutical & medtech companies with insurance claims data partners.
- In May 2026, Sino Biological, Inc. unveiled its groundbreaking XPressMAX Cell-Free Protein Synthesis Kit, a cutting-edge solution to supercharge AI-powered high-throughput screening pipelines for antibody drug discovery.
- In March 2026, MDClone launched ADAMS Copilot, its AI-enabled healthcare data assistant, to revolutionize how clinical, operational, quality, & research teams explore & work on real-world data.
- In March 2026, Hoth Therapeutics, Inc. explored OpenClaw, a sophisticated AI-driven computational platform to foster drug discovery, boost data-driven decision-making, & reveal value across its therapeutic pipeline.
Conclusion
A need for massive time & capital spending in the traditional R&D process, AI supports resolving these concerns and promoting resource allocation. A key catalyst is the breakthroughs in cloud computing, quantum computing, & graphics processing units (GPUs), which allow the processing of vast molecular & biological datasets. In the case of drug discovery, AI is assisting in the estimation of absorption, distribution, metabolism, and excretion, along with probable toxicities, mitigating late-stage clinical trial failures.
About the Experts
Aditi Shivarkar
Aditi leads as Vice President at Towards Healthcare and brings over 15 years of experience in healthcare research, innovation, and strategy. She works closely with data from across the healthcare sector and turns it into clear direction that companies can actually use. Her work covers pharmaceuticals, medical devices, and digital health. She helps businesses understand where the market is going and how to respond with confidence. Aditi focuses on practical thinking, strong decision-making, and delivering real results that make a difference.
Aman Singh
Aman Singh brings over 13 years of experience in healthcare research and consulting. He studies global healthcare trends and keeps a close eye on areas like biotech, AI in healthcare, and new treatment approaches. At Towards Healthcare, he leads the research team and makes sure the work stays accurate, useful, and easy to understand. Aman breaks down complex changes in the industry and helps businesses make smart, informed decisions.
Piyush Pawar
Piyush Pawar works as Senior Manager for Sales and Business Growth at Towards Healthcare, with more than 10 years of experience in the healthcare space. He works directly with clients and helps them find the right research for their needs. He makes sure clients understand the insights and know how to use them in their business. Piyush builds strong relationships and focuses on helping companies grow by turning research into clear, practical action.
